Dr. med. Cäcilie Wismeth

Oberärztin NeuroOnkologie

Klinik und Poliklinik für Neurologie der Universität Regensburg Am Bezirksklinikum Universitätsstraße 84 D-93053 Regensburg

Tel.: +49 (941) 941 0 Fax: +49 (941) 941 3155 caecilia.wismeth@medbo.de

Klinische Qualifikationen

Klinisch-wissenschaftliche Interessen

• NeuroOnkologie
  

Links

• NeuroOnkologie

Publikationen

1. Caecilia Wismeth, M.D.1,4, Peter Hau, M.D.1,4, Klaus Fabel, M.D.3, Ulrike Baumgart, M.D.1, Birgit Hirschmann, R.N. 1, Horst Koch, M.D., Ph.D.1, Tanja Jauch, R.N.1, Oliver Grauer, M.D.1, Lisa Drechsel, M.D.1, Alexander Brawanski, M.D.2, Ulrich Bogdahn M.D.1, and Andreas Steinbrecher, M.D.1 Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy - a Phase II-Study, Journal of Neuro-Oncology, submitted 11/2003
2. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W, Bogdahn U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer. 2001;92(7):1936-42.

Übersichtsartikel:

1. Hau P, Wismeth C, Bogdahn U. Recent Advances in the Chemotherapy of Patients with High-Grade Glioma after First-Line Therapy in the Situations of Stable and Recurrent Disease. Recent Advances in Cancer 2002;2:265- 278.

Abstracts:

1. Hau P, Wismeth C, Fabel-Schulte K, Dietrich J, Steinbrecher A, Angerer M, Krauseneck P, Bogdahn U. Prevention of deep vein thrombosis and severe infection by low-molecular heparin and i.v. polyvalent immunoglobulins in patients with high-grade glioma under chemotherapy. Proceedings of the ASCO 2000;2523 (abstract).
2. Dietrich J, Fabel-Schulte K, Hau P, Wismeth C, Angerer M, Steinbrecher A, Ulrich W, Brawanski A, Bogdahn U. Liposomal doxorubicin (caelyx) in the treatment of recurrent high-grade glioma - a phase ii/iii study. Proceedings of the ASCO 2000;661 (abstract).
3. Hau P, Fabel K, Wismeth C, Jauch T, Steinbrecher A, Bogdahn U. 13-cis- retinoid acid as a new treatment strategy in patients with high-grade glioma who show stable disease after first-line treatment. J Cancer Res Clin Oncol 2002;489 (abstract).